MedPath

Oxygen

Generic Name
Oxygen
Brand Names
Alnox, Ez-OX, Heliox, Oxygen, Southern Medical
Drug Type
Small Molecule
Chemical Formula
O2
CAS Number
7782-44-7
Unique Ingredient Identifier
S88TT14065
Background

Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in an attempt to oxygenate the lungs. Oxygen therapy is used to treat emphysema, pneumonia, some heart disorders (congestive heart failure), some disorders that cause increased pulmonary artery pressure, and any disease that impairs the body's ability to take up and use gaseous oxygen. Higher level of oxygen than ambient air (hyperoxia) can be introduced under normobaric or hyperbaric conditions.

Indication

Oxygen therapy in clinical settings is used across diverse specialties, including various types of anoxia, hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses, trauma, poisonings and drug overdoses. Oxygen therapy tries to achieve hyperoxia to reduce the extent of hypoxia-induced tissue damage and malfunction.

Associated Conditions
Anemia, Cancer, Hypoxemia, Hypoxia, Migraine, Polycythemia, Pulmonary Hypertension (PH), Respiratory Disorders, Sleep Apnea
Associated Therapies
-

Oxygen Therapy in Schizophrenia

Phase 3
Conditions
Chronic Schizophrenia
First Posted Date
2007-09-06
Last Posted Date
2008-05-28
Lead Sponsor
Beersheva Mental Health Center
Target Recruit Count
20
Registration Number
NCT00525863
Locations
🇮🇱

Beersheva Mental Health Center, Beersheva, Israel

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

Phase 2
Terminated
Conditions
Periventricular Leukomalacia
Prematurity
Bronchopulmonary Dysplasia
Intraventricular Hemorrhage
Interventions
Drug: inhaled nitric oxide
Drug: oxygen
First Posted Date
2007-08-13
Last Posted Date
2024-10-17
Lead Sponsor
University of Chicago
Target Recruit Count
273
Registration Number
NCT00515281
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

Heliox-Powered Albuterol Therapy in the Treatment of Children Admitted With Acute Asthma Exacerbation

Phase 2
Terminated
Conditions
Status Asthmaticus
Interventions
First Posted Date
2006-12-12
Last Posted Date
2010-11-07
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Target Recruit Count
42
Registration Number
NCT00410150
Locations
🇺🇸

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Helium-Hyperoxia and 6MWT Distance in COPD

Not Applicable
Completed
Conditions
Chronic Obstructive Pulmonary Disease
First Posted Date
2006-10-31
Last Posted Date
2006-10-31
Lead Sponsor
University of Saskatchewan
Target Recruit Count
16
Registration Number
NCT00394225
Locations
🇨🇦

Edmonton General Hospital, Caritas Lung HEalth Centre, Edmonton, Alberta, Canada

Supplemental Oxygen and Complications After Abdominal Surgery (The PROXI-trial)

Phase 4
Completed
Conditions
Laparotomy
Interventions
First Posted Date
2006-08-16
Last Posted Date
2009-10-16
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
1400
Registration Number
NCT00364741
Locations
🇩🇰

Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark

🇩🇰

Kolding Hospital, Kolding, Denmark

🇩🇰

Naestved Hospital, Naestved, Denmark

and more 11 locations

Effects of Supplementary Oxygen on Dyspnoea and Exercise Tolerance in COPD Patients Given LTOT

Not Applicable
Completed
Conditions
COPD
First Posted Date
2005-11-07
Last Posted Date
2007-04-13
Lead Sponsor
LHL Helse
Target Recruit Count
20
Registration Number
NCT00249093
Locations
🇳🇴

Glittreklinikken, Hakadal, Norway

Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis

Phase 2
Terminated
Conditions
Sickle Cell Disease
Interventions
First Posted Date
2005-09-02
Last Posted Date
2023-02-23
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
18
Registration Number
NCT00142051
Locations
🇺🇸

Children's Hospital Boston, Boston, Massachusetts, United States

Heliox-Driven Racemic Epinephrine in Treatment of Bronchiolitis in Pediatric ED Patients

Phase 3
Completed
Conditions
Bronchiolitis
Interventions
First Posted Date
2005-06-30
Last Posted Date
2020-05-20
Lead Sponsor
University of Louisville
Target Recruit Count
72
Registration Number
NCT00116584
Locations
🇺🇸

Kosair Children's Hospital, Louisville, Kentucky, United States

Inhaled Nitric Oxide in Neonates With Elevated A-a DO2 Gradients Not Requiring Mechanical Ventilation

Phase 1
Terminated
Conditions
Respiratory Acidosis
Lung Disease
Hypoxemia
Interventions
Drug: nitric oxide for inhalation
Drug: Oxygen
First Posted Date
2002-07-11
Last Posted Date
2016-10-19
Lead Sponsor
Mallinckrodt
Target Recruit Count
7
Registration Number
NCT00041548
Locations
🇺🇸

The University of Alabama Birmingham, Birmingham, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath